Physician profile
Alan M Bigman
NPI 1215975701
$39,567.95
in general payments reported to CMS, 2019-2025
23 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $7,044 · 2021: $760 · 2022: $831 · 2023: $532 · 2024: $866 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36,034.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $714.83 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $529.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $445.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $309.57 | 2021-2024 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.23 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $170.50 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $155.31 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $154.61 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.83 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $103.62 | 2023-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $102.42 | 2019-2021 | |
| Eisai INC. | $96.44 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $86.76 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $56.01 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.01 | 2019-2020 | |
| Viiv Healthcare Company | $47.07 | 2023-2024 | Apretude |
| Seqirus USA INC | $41.69 | 2023-2025 | Fluad Quadrivalent, Flucelvax Quadrivalent, Flucelvax |
| Vbi Vaccine (Delaware) INC. | $41.39 | 2022 | |
| Sanofi Pasteur INC. | $28.16 | 2022-2023 | |
| Global Blood Therapeutics, INC. | $24.12 | 2021 | |
| Genentech USA, INC. | $23.01 | 2021 | |
| Althera Pharmaceuticals LLC | $22.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.